Inovio Pharmaceuticals, Inc.

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
11.31 ^USD	+2.45%		+26.65%	+84.80%

Jul. 11	INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway	CI
Jul. 02	Inovio Pharmaceuticals Names Steven Egge Chief Commercial Officer	MT

INOVIO Appoints Mammen Mammen as Senior Vice President, Clinical Development

June 25, 2020 at 11:01 pm EDT

INOVIO announced that Mammen (Anza) Mammen joins INOVIO as Senior Vice President, Clinical Development. Dr. Mammen will report to Dr. Laurent Humeau, INOVIO's CSO.

Latest news about Inovio Pharmaceuticals, Inc.

INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway	Jul. 11	CI
Inovio Pharmaceuticals Names Steven Egge Chief Commercial Officer	Jul. 02	MT
INOVIO Appointsof Steven Egge as Chief Commercial Officer	Jul. 02	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell Small Cap Completeness Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 2000 Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 3000E Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell Microcap Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 2500 Value Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 3000 Value Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 2000 Value Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 2000 Dynamic Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell Microcap Value Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 2500 Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 3000 Index	Jun. 30	CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 3000E Value Index	Jun. 30	CI
Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target	May. 14	MT
Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	Apr. 16	MT
Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	Apr. 16	MT
Top Premarket Decliners	Apr. 16	MT
Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target	Jan. 25	MT

Chart Inovio Pharmaceuticals, Inc.

Duration

Period

More charts

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Inovio Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.31 USD

Average target price

18.92 USD

Spread / Average Target

+67.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INOVIO PHARMACEUTICALS, INC.	+84.80%	293M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research

Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Biotechnology & Medical Research

INOVIO Appoints Mammen Mammen as Senior Vice President, Clinical Development

Latest news about Inovio Pharmaceuticals, Inc.

Chart Inovio Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Ratings for Inovio Pharmaceuticals, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research